New 4-aryl-1,4-dihydropyridines and 4-arylpyridines as P-glygoprotein inhibitors

Drug Metabolism and Disposition

Volumn 33, Issue 3, 2005, Pages 321-328

  Zhou, Xiao Fei ^a   Zhang, Linping ^a   Tseng, Elaine ^a   Scott Ramsay, Elizabeth ^a   Schentag, Jerome J ^a   Coburn, Robert A ^a   Morris, Marilyn E ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL; DAUNORUBICIN; DIHYDROPYRIDINE DERIVATIVE; GLYCOPROTEIN P INHIBITOR; NIGULDIPINE; PYRIDINE DERIVATIVE; VINBLASTINE;

ARTICLE; BINDING ASSAY; BRAIN CORTEX; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE;

ANIMALS; BINDING, COMPETITIVE; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; CELL LINE, TUMOR; CEREBRAL CORTEX; DAUNORUBICIN; DIHYDROPYRIDINES; HUMANS; P-GLYCOPROTEIN; PYRIDINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; VINBLASTINE;

EID: 14044250851     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.002089     Document Type: Article

References (38)

1. Aebi S, Schnider TW, Los G, Heath DD, Darrah D, Kirmani S, McClay EF, D'Agostino H, Plaxe SC, Fink D, et al. De las Alas MM, Howell SB and Christen RD (1999) A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel. Cancer Chemother Pharmacol 44:259-265.
2. Bhat UG, Winter MA, Pearce HL, and Beck WT (1995) A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of multidrug resistancel and P-glycoprotein in a human colon carcinoma cell line. Mol Pharmacol 48:682-689.
3. Boer R, Grassegger A, Schudt C, and Glossmann H (1989) (+)-Niguldipine binds with very high affinity to Ca2+ channels and to a subtype of alpha 1-adrenoceptors. Eur J Pharmacol 172:131-145.
4. Boer R, Haas S, and Schodl A (1994) Influence of dexniguldipine-HCl on rhodamine-123 accumulation in a multidrug-resistant leukaemia cell line: comparison with other chemosensitisers. Eur J Cancer 30A:1117-1123.
5. 3H]nitrendipine to guinea pig ileal smooth muscle. J Pharmacol Exp Ther 225:291-309.
6. Coburn RA, Wierzba M, Suto MJ, Solo AJ, Triggle AM, and Triggle DJ (1988) 1,4-Dihydropyridine antagonist activities at the calcium channel: a quantitative structure-activity relationship approach. J Med Chem 31:2103-2107.
7. Collin JN (1884) Ueber die Einwirkung des Ammoniaks auf Acetessigester. Justus Liebeigs Ann Chem 226:294-322.
8. Di Stilo A, Visentin S, Cena C, Gasco AM, Ermondi G, and Gasco A (1998) New 1,4-dihydropyridines conjugated to furoxanyl moieties, endowed with both nitric oxide-like and calcium channel antagonist vasodilator activities. J Med Chem 41:5393-5401.
9. Echizen H, Brecht T, Niedergesass S, Vogelgesang B, and Eichelbaum M (1985) The effect of dextro-, levo- and racemic verapamil on atrioventricular conduction in humans. Am Heart J 109:210-217.
10. Ferry DR, Glossmann H, and Kaumann AJ (1985) Relationship between the stereoselective negative inotropic effects of verapamil enantiomers and their binding to putative calcium channels in human heart. Br J Pharmacol 84:811-824.
11. Futscher BW, Foley NE, Gleason-Guzman MC, Meltzer PS, Sullivan DM, and Dalton WS (1996) Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance. Int J Cancer 66:520-525.
12. Gekeler V, Boer R, Uberall F, Ise W, Schubert C, Utz I, Hofmann J, Sanders KH, Schachtele C, Klemm K, and Grunicke H (1996) Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance. Br J Cancer 74:897-905.
13. Giaccone G, Linn SC, and Pinedo HM (1995) Multidrug resistance in breast cancer: mechanisms, strategies. Eur J Cancer 31A (Suppl 7):S15-S17.
14. Graziadei I, Zernig G, Boer R, and Glossman H (1989) Stereoselective binding of niguldipine enantiomers to alpha 1A-adrenoceptors labeled with [3H]5-methyl-urapidil. Eur J Pharmacol 172:329-337.
15. Haussermann K, Benz B, Gekeler V, Schumacher K, and Eichelbaum M (1991) Effects of verapamil enantiomers and major metabolites on the cytotoxicity of vincristine and daunomycin in human lymphoma cell lines. Eur J Clin Pharmacol 40:53-59.
16. Hofmann J, Gekeler V, Ise W, Noller A, Mitterdorfer J, Hofer S, Utz I, Gotwald M, Boer R, Glossmann H, et al. (1995) Mechanism of action of dexniguldipine-HCl (B8509-035), a new potent modulator of multidrug resistance. Biochem Pharmacol 49:603-609.
17. Kamath N, Grabowski D, Ford J, Drake F, Kerrigan D, Pommier Y, and Ganapathi R (1991) Trifluoperazine modulation of resistance to the topoisomerase II inhibitor etoposide in doxorubicin resistant L1210 murine leukemia cells. Cancer Commun 3:37-44.
18. Kamiwatari M, Nagata Y, Kikuchi H, Yoshimura A, Sumizawa T, Shudo N, Sakoda R, Seto K, and Akiyama S (1989) Correlation between reversing of multidrug resistance and inhibiting of [3H]azidopine photolabeling of P-glycoprotein by newly synthesized dihydropyridine analogues in a human cell line. Cancer Res 49:3190-3195.
19. Kawashima Y, Ogawa T, Kato M, Nakazato A, Tsuchida K, Hatayama K, Hirono S, and Moriguchi I (1993) Structure-activity study of antihypertensive 1,4-dihydropyridine derivatives having nitrooxyalkyl moieties at the 3 and 5 positions. Chem Pharm Bull (Tokyo) 41:1060-1065.
20. Kruijtzer CM, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC, Paul EM, and Schellens JH (2002) Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 20:2943-2950.
21. List AF, Kopecky KJ, Willman CL, Head DR, Slovak ML, Douer D, Dakhil SR, and Appelbaum FR (2002) Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase. Blood 100:1910-1912.
22. Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD, Miyake K, Resau JH, and Bates SE (2000) The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 113 (Pt 11):2011-2021.
23. Liu J, Bangalore R, Rutledge A, and Triggle DJ (1994) Modulation of L-type Ca2+ channels in clonal rat pituitary cells by membrane depolarization. Mol Pharmacol 45:1198-1206.
24. Loev B, Goodman MM, Snader MK, Tedeschi R, and Macko E (1974) "Hantzsch-type" dihydropyridine hypotensive agents. 3. J Med Chem 17:956-965.
25. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, and Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-1112.
26. Sumizawa T, Chen ZS, Chuman Y, Seto K, Furukawa T, Haraguchi M, Tani A, Shudo N, and Akiyama SI (1997) Reversal of multidrug resistance-associated protein-mediated drug resistance by the pyridine analog PAK-104P. Mol Pharmacol 51:399-405.
27. Szabo D and Molnar J (1998) The role of stereoselectivity of chemosensitizers in the reversal of multidrug resistance of mouse lymphoma cells. Anticancer Res 18:3039-3044.
28. Tasaka S, Ohmori H, Gomi N, Iino M, Machida T, Kiue A, Naito S, and Kuwano M (2001) Synthesis and structure-activity analysis of novel dihydropyridine derivatives to overcome multidrug resistance. Bioorg Med Chem Lett 11:275-277.
29. Trock BJ, Leonessa F, and Clarke R (1997) Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 89:917-931.
30. Tsuruo T, Iida H, Tsukagoshi S, and Sakurai Y (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1967-1972.
31. Tsuruo T, Iida H, Tsukagoshi S, and Sakurai Y (1983) Potentiation of vincristine and Adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors. Cancer Res 43:2267-2272.
32. Vanhoefer U, Cao S, Minderman H, Toth K, Scheper RJ, Slovak ML, and Rustum YM (1996) PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein. Clin Cancer Res 2:369-377.
33. Walker D and Hiebert JD (1967) 2,3-Dichloro-5,6-dicyanobenzoquinone and its reactions. Chem Rev 67:153-195.
34. Wetzel JM, Miao SW, Forray C, Borden LA, Branchek TA, and Gluchowski C (1995) Discovery of alpha 1a-adrenergic receptor antagonists based on the L-type Ca2+ channel antagonist niguldipine. J Med Chem 38:1579-1581.
35. Wigler PW (1999) PSC833, cyclosporin A and dexniguldipine effects on cellular calcein retention and inhibition of the multidrug resistance pump in human leukemic lymphoblasts. Biochem Biophys Res Commun 257:410-413.
36. Wilson WH, Jamis-Dow C, Bryant O, Balis FM, Klecker RW, Bates SE, Chabner BA, Steinberg SM, Kohler DR, and Wittes RE (1995) Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. J Clin Oncol 13:1985-1994.
37. Zochbauer-Muller S, Filipits M, Rudas M, Brunner R, Krajnik O, Suchomel R, Schmid K, and Pirker R (2001) P-glycoprotein and MRP1 expression in axillary lymph node metastases of breast cancer patients. Anticancer Res 21:119-124.
38. Zoeller J and Sumner CE Jr (1990) Sequential acetalization-pyrolysis of alpha-acetylcinnamates and alpha-acetylbenzalacetones. A method for the generation of 2-carbonyl-substituted naphthalenes. J Org Chem 55:319-324.